3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Other
1
Myeloid
1
Lymphoid
1
Conditions
Lymphoma, Non-Hodgkin
2
Hodgkin Disease
2
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Mucositis
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Interventions
Cyclophosphamide
54
fludarabine phosphate
48
Peripheral Blood Stem Cell Transplantation
37
Tacrolimus
36
Mycophenolic Acid
35
Whole-Body Irradiation
30
Busulfan
29
Antilymphocyte Serum
26
Cyclosporine
23
Methotrexate
21
fludarabine
19
Melphalan
18
Filgrastim
18
Radiotherapy
13
Methylprednisolone
12
Etoposide
12
Cord Blood Stem Cell Transplantation
12
thymoglobulin
11
Sirolimus
11
Psychiatric Rehabilitation
9
Flow Cytometry
9
Stem Cell Transplantation
7
Granulocyte Colony-Stimulating Factor
7
Therapeutics
6
sargramostim
5
ruxolitinib
5
Specimen Handling
5
Polymerase Chain Reaction
5
Cytarabine
5
Cyclosporins
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Primary Myelofibrosis
×
angiotensin I (1-7)
×
Lymphoid
×
Clear all
NCT01300611
2020-12-08
USBTXA127CBT
Tarix Pharmaceuticals
Phase 1
Terminated
20 enrolled